SmithKline Beecham/Texas Bio argatroban
Executive Summary
SmithKline will launch anticoagulant argatroban without a separate brand name. The Texas Biotechnology product was approved by FDA June 30 for prevention and treatment of heparin-induced thrombocytopenia under the name Acova; the original trade name Novastan was rejected by FDA as too similar to Immunex' Novantrone, and SB determined that Acova also raised a potential trademark conflict (1"The Pink Sheet" July 10, p. 4). The decision to launch the product using only the generic name followed "extended discussions with FDA," Texas Biotechnology said. "Ultimately, we wanted a name that physicians would readily recognize, as well as one that would allow us to get to market as soon as possible," SB said
You may also be interested in...
SmithKline Beecham Argatroban
Wholesale acquisition cost for anticoagulant is $600 per vial. SmithKline launched the drug Nov. 13 and plans to support medical education programs for the diagnosis and treatment of heparin-induced thrombocytopenia. Argatroban was approved June 30 (1"The Pink Sheet" Oct. 2, In Brief)
SmithKline Beecham Argatroban
Wholesale acquisition cost for anticoagulant is $600 per vial. SmithKline launched the drug Nov. 13 and plans to support medical education programs for the diagnosis and treatment of heparin-induced thrombocytopenia. Argatroban was approved June 30 (1"The Pink Sheet" Oct. 2, In Brief)
SmithKline Argatroban Detailing To Encourage Early Identification Of HIT
SmithKline Beecham reps will encourage early identification of heparin-induced thrombocytopenia by physicians in their marketing of Texas Biotechnology's direct thrombin inhibitor argatroban.